Creative Diagnostics Launches Epigenetics Antibodies for Bio-research Communities

Creative Diagnostics recently launches epigenetics antibodies to global academic, pharmaceutical and biotech communities.

As a leading supplier of high quality antibodies validated for use in multiplexed assays, Creative Diagnostics recently launches epigenetics antibodies to global academic, pharmaceutical and biotech communities for specific and reproducible epigenetic target detection. Now highly specific antibodies are available at Creative Diagnostics to most histone modifications validated in CHIP.

In 1957, Conrad Waddington coined a term Epigenetics to describe how a gene interacts with its surrounding to produce a phenotype. Since then, people use Epigenetic to define a phenomenon that changes the final outcome of gene expression without changing the underlying DNA sequence. In recent decades, the mechanism of Epigenetics can be mainly classified into three groups: DNA Methylation, Histone modification and noncoding RNA.

DNA Methylation is one of the most broadly studied and well-characterized epigenetic modifications mechanisms, which usually occurs at cytosine-phosphate-guanosine (CpG) islands by adding a methylated group at cytosine; Histone modification mainly includes acetylation, methylation, phosphorylation, and ubiquitylation on the histone tails. These modifications take places through many other transcriptional factors, such as HATs, Sirtuins, HDMs, HDAC, and HMTs; Noncoding RNA (ncRNA) is a third subgroup of epigenetics mechanism, which is transcribed from DNA but not translated into protein. They are regulators of site specific modification and imprinted gene-silencing.

“Actually, we have currently offered hundreds of antibodies against other epigenetic and transcription factors. And our growing portfolio of antibodies for epigenetics research have been developed using Hi-Affi™ antibody technology to create recombinant mouse monoclonal Fab antibodies. The Hi-Affi™ antibody is not susceptible to cell-line drift or lot-to-lot variation, but it provides researchers with best specificity and performance,” said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.

“These newly released antibodies are useful tools for researchers to detect and characterize epigenetics targets with exceptional specificity to particular post-translational modifications and reproducibility in the form of antibody lot-to-lot consistency. All of our unique antibodies have been validated for multiple applications to ensure quality, such as ELISA and immunoprecipitation, and they are also suitable for immunoblotting, and immunofluorescence. No matter what your research needs are, attention to lab performance is always given to all of our epigenetics antibodies,” added Dr. Randy S. Vaughn, senior researcher, Creative Diagnostics.  

If you want to know more information about epigenetics and available antibodies, please contact Creative Diagnostics at 1-631-619-7922 or email to [email protected]

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers’ assay development and manufacturing needs.

Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: NY
Country: United States
Website: www.creative-diagnostics.com